Mar 27, 2024 4:05pm EDT Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Mar 25, 2024 8:00am EDT Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Mar 22, 2024 9:15am EDT Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Mar 22, 2024 6:30am EDT Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Feb 26, 2024 8:00am EST Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
Feb 20, 2024 7:30am EST Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
Dec 27, 2023 7:30am EST Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
Dec 21, 2023 7:30am EST Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
